Vericel Q4 revenue rises 23%, beats estimates

Overview

• Advanced therapies company's Q4 revenue rose 23%, beating analyst expectations

• Net income for Q4 increased 17% yr/yr

• Company achieved record Q4 gross margin of 79%

Outlook

• Vericel forecasts 2026 total revenue between $316 mln and $326 mln

• Company expects MACI revenue of $280 mln to $286 mln in 2026

• Vericel anticipates gross margin of approximately 75% for 2026

Result Drivers

• MACI REVENUE GROWTH - MACI revenue grew 23% in Q4, contributing significantly to total revenue growth

• SALES FORCE EXPANSION - Completed MACI sales force expansion, contributing to increased revenue

• FACILITY COSTS - Increased operating expenses due to new Burlington facility costs

Company press release: ID:nGNX4Wkb8x

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Vericel Corp is $56.50, about 52.3% above its February 25 closing price of $37.09

• The stock recently traded at 67 times the next 12-month earnings vs. a P/E of 63 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.